ERBB2 and breast carcinoma: Through cellular engineering aimed at bolstering the expression of anti‐HER2 antibodies within EV‐based mRNA, researchers have attained heightened targeting efficacy against breast cancer with abundant HER2, thereby curbing cancer progression [28].